The article " 2 Generic Drug Stocks Ready to Surge in 2025 " first appeared on MarketBeat.

Annual performance reviews can be valuable experiences for both leadership and employees if approached strategically. However, to be effective, these reviews should be a two-way conversation that ...

It also backs its platform with a Happiness Guarantee. As a new homeowner, I didn't know where to go to compare prices and reviews and get honest information, but so far, HomeAdvisor has been the ...

Sales growth was mainly driven by higher revenues from generic products globally and strong growth from branded drugs, Austedo, Ajovy and Uzedy. Sales of certain product rights in Europe and ...

EPS: Up 16%. Free Cash Flow: $922 million. AUSTEDO Revenue: $435 million, 28% growth. AJOVY Revenue: 21% growth. UZEDY Revenue: $35 million in Q3, year-to-date $75 million. Global Generics Growth ...